The IPO provides critical capital to fund operations and advance the STX-1150 Phase 1 trial through H1 2027 data readout. Monitor enrollment progress and initial safety/efficacy data for STX-1150 as the primary catalyst. The company's strong collaboration revenue ($51.2M in 2025) provides some non-dilutive funding, but ongoing losses and going concern risk underscore the importance of this public offering. Valuation at $14 midpoint implies ~$226M market cap pre-money, with significant dilution to existing holders.
Executive Summary
Scribe Therapeutics, a clinical-stage CRISPR biotech engineering in vivo genetic medicines for cardiovascular disease, filed an amended S-1 for its IPO. The company is offering 7,150,000 shares at an estimated $13-$15 range (midpoint $14), with a concurrent $7.5M private placement by Sanofi, targeting net proceeds of ~$96.2M. Proceeds will fund the Phase 1 trial of lead candidate STX-1150 (PCSK9 epigenetic silencing) and advance two preclinical programs. The company has no approved products, is pre-revenue on product sales, and its auditor expressed substantial doubt about its ability to continue as a going concern, making this IPO a critical capital event.
Key Financial Metrics
Key Facts
- IPO of 7,150,000 shares at $13-$15 per share, midpoint $14, plus 30-day underwriter option for 1,072,500 additional shares
- Concurrent private placement of ~$7.5M by Sanofi (535,714 shares at IPO price), contingent on IPO closing
- Estimated net proceeds of ~$96.2M ($110.2M if overallotment exercised)
- Lead candidate STX-1150 (ELXR epigenetic silencing of PCSK9) in Phase 1 trial in Australia, initial data expected H1 2027
- Collaboration revenue of $51.2M in FY2025, net loss of $21.8M, accumulated deficit of $175.1M as of March 31, 2026
- Going concern warning: existing cash of $49.7M insufficient for 12 months without IPO proceeds
- Strategic collaborations with Sanofi (sickle cell disease) and Lilly (neurological/neuromuscular disorders)
Financial Impact
IPO net proceeds of ~$96.2M after underwriting discounts and expenses, plus $7.5M from Sanofi private placement, extending cash runway into first half of 2029
Risk Factors
- Pre-revenue with no approved products; history of recurring losses and going concern warning
- Lead candidate STX-1150 is in early Phase 1; clinical failure risk is high
- CRISPR-based epigenetic silencing is unproven in humans for therapeutic use
- Intense competition from established PCSK9 therapies (Repatha, Praluent, Leqvio) and other gene editing companies (Intellia, CRISPR Therapeutics, Verve)
- Significant dilution from IPO and concurrent private placement (7.7M new shares vs. 8.5M pre-offering)
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001193125-26-308330 |
| Document: d21355dex1013.htm | 0001193125-26-308330 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 7w ago | 8-K | $30.81 $16.79 | ▼ −45.50% | ▼ −44.32% | $15.48 (−49.76%) |
Sep 2, 2026 7w ago | Press Release | $30.81 $16.79 | ▼ −45.50% | ▼ −44.32% | $15.48 (−49.76%) |
Jul 29, 2026 12w ago | Insider Cluster | $20.40 $28.84 | ▲ +41.37% | ▲ +37.41% | $15.48 (−24.12%) |
Jul 29, 2026 12w ago | Insider Cluster | $20.40 $28.84 | ▲ +41.37% | ▲ +37.41% | $15.48 (−24.12%) |
Jul 28, 2026 12w ago | Insider Cluster | $18.36 $31.70 | ▲ +72.66% | ▲ +67.64% | $15.48 (−15.69%) |
Jul 24, 2026 13w ago | 424B4 | $18.97 $37.25 | ▲ +96.36% | ▲ +93.06% | $15.48 (−18.40%) |
Jul 24, 2026 13w ago | EFFECT | $21.65 $34.13 | ▲ +57.64% | ▲ +54.02% | $15.48 (−28.50%) |
Jul 23, 2026 13w ago | 3 / PRESS-RELEASE | $21.65 $34.13 | ▲ +57.64% | ▲ +54.02% | $15.48 (−28.50%) |
Jul 20, 2026 14w ago | S-1/A | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers